NCT03611569View on ClinicalTrials.gov

Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

July 25, 2018

Primary Completion Date

July 26, 2021

Study Completion Date

July 26, 2021

Conditions
HealthyParkinson Disease
Interventions
DRUG

Lu AF82422

Lu AF82422 - concentrate for solution for infusion; vials containing 50mg/ml, single dose

DRUG

Placebo

placebo - concentrate for solution for infusion, single dose

Trial Locations (4)

21225

Parexel, Early Phase Clinical Unit (EPCU), Harbor Hospital, Baltimore

32806

PPD, Orlando

33024

Reserach Center of America, Hollywood

91206

California Clinical Trials Medical Group (CCTMG), Glendale

All Listed Sponsors
lead

H. Lundbeck A/S

INDUSTRY

NCT03611569 - Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's Disease | Biotech Hunter | Biotech Hunter